Join Fund Library now and get free access to personalized features to help you manage your investments.

BMO ARK Genomic Revolution Fund Series A

Sector Equity

Fundata ESG GradeE Click for more information on Fundata’s ESG Grade

Fundata ESG Grade E

Click for more information on Fundata’s ESG Grade.

NAVPS
(11-22-2024)
$7.20
Change
$0.19 (2.67%)

As at October 31, 2024

As at October 31, 2024

As at July 31, 2024

Period
Loading...

Legend

BMO ARK Genomic Revolution Fund Series A

Compare Options


Fund Returns

Inception Return (November 04, 2022): -15.12%

Fund Returns
Row Heading Return Annualized Return
1 Mth 3 Mth 6 Mth YTD 1 Yr 2 Yr 3 Yr 4 Yr 5 Yr 6 Yr 7 Yr 8 Yr 9 Yr 10 Yr
Fund -6.81% -12.85% 0.76% -25.86% 0.15% - - - - - - - - -
Benchmark 0.85% 5.30% 12.95% 18.24% 32.06% 15.16% 8.05% 15.02% 11.33% 11.65% 9.36% 9.62% 9.96% 8.41%
Category Average -0.55% 1.27% 9.75% 16.69% 32.21% 20.51% 3.93% 10.09% 11.90% 11.88% 11.02% 12.06% 11.03% 11.60%
Category Rank 199 / 200 194 / 195 178 / 191 188 / 189 184 / 189 - - - - - - - - -
Quartile Ranking 4 4 4 4 4 - - - - - - - - -

Monthly Return

Monthly Return
Return % Nov Dec Jan Feb Mar Apr May Jun Jul Aug Sep Oct
Fund 17.40% 15.07% -11.82% 11.31% -8.88% -17.74% 4.36% -3.64% 14.97% -4.02% -2.56% -6.81%
Benchmark 7.48% 3.91% 0.55% 1.82% 4.14% -1.82% 2.77% -1.42% 5.87% 1.22% 3.15% 0.85%

Best Monthly Return Since Inception

17.40% (November 2023)

Worst Monthly Return Since Inception

-17.74% (April 2024)

Calendar Return (%)

Calendar Return
Return % 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023
Fund - - - - - - - - - 11.84%
Benchmark 10.55% -8.32% 21.08% 9.10% -8.89% 22.88% 5.60% 25.09% -5.84% 11.75%
Category Average 17.30% 16.21% -0.43% 20.39% 1.55% 22.37% 29.99% 15.34% -25.24% 26.53%
Quartile Ranking - - - - - - - - - 3
Category Rank - - - - - - - - - 91/ 161

Best Calendar Return (Last 10 years)

11.84% (2023)

Worst Calendar Return (Last 10 years)

11.84% (2023)

Asset Allocation

Asset Allocation
Name Percent
US Equity 88.46
International Equity 7.43
Cash and Equivalents 3.45
Canadian Equity 0.66

Sector Allocation

Sector Allocation
Name Percent
Healthcare 88.94
Technology 3.87
Cash and Cash Equivalent 3.45
Industrial Goods 0.78
Other 2.96

Geographic Allocation

Geographic Allocation
Name Percent
North America 92.58
Europe 7.43
Other -0.01

Top Holdings

Top Holdings
Name Percent
Twist Bioscience Corp 7.97
CRISPR Therapeutics AG 6.68
Recursion Pharmaceuticals Inc Cl A 6.63
CareDx Inc 5.14
Adaptive Biotechnologies Corp 4.41
Veracyte Inc 4.36
Ionis Pharmaceuticals Inc 4.18
Nurix Therapeutics Inc 4.02
10X Genomics Inc 3.66
Intellia Therapeutics Inc 3.57

Equity Style

Market capitalization is medium. Equity style is growth.

Fixed Income Style

Fixed income style data not available

Risk vs Return (3 Yr)

3 Yr Annualized

Standard Deviation - - -
Beta - - -
Alpha - - -
Rsquared - - -
Sharpe - - -
Sortino - - -
Treynor - - -
Tax Efficiency - - -
Volatility - - -

Risk Rating

Rating  out of ten

Annualized Key Ratio Period Comparison

Key Ratio
Key Ratio 1 Yr 3 Yr 5 Yr 10 Yr
Standard Deviation 40.61% - - -
Beta 3.18% - - -
Alpha -0.83% - - -
Rsquared 0.56% - - -
Sharpe 0.07% - - -
Sortino 0.18% - - -
Treynor 0.01% - - -
Tax Efficiency - - - -

Fundata ESG Metrics

Fundata ESG Score

The E, S, and G scores are averaged for each security in the portfolio, to arrive at an ESG score for each security. We take the portfolio weighted average of the ESG scores for each fund and rank them against their peers to arrive at the Fundata ESG Score from 0-100.

Fundata E Score

Three scores under the Environment bucket are averaged to yield the Fundata Environment Score for each fund from 0-100: (1) Pollution Prevention, (2) Environmental Transparency, (3) Resource Efficiency.

Fundata S Score

Six scores under the Social bucket are averaged to yield the Fundata Social Score for each fund from 0-100. (1) Compensation and Satisfaction, (2) Diversity and Rights, (3) Education and Work Conditions, (4) Community and Charity, (5) Human Rights, (6) Sustainability Integration.

Fundata G Score

Three scores under the governance bucket are averaged to yield the Fundata Governance Score for each fund from 0-100: (1) Board Effectiveness, (2) Management Ethics, (3) Disclosure and Accountability.

Powered by OWL Analytics. For more information, please contact Fundata Canada.

Fund Details

Start Date November 04, 2022
Instrument Type Mutual Fund
Share Class Commission Based Advice
Legal Status Trust
Sales Status Open
Currency CAD
Distribution Frequency Annual
Assets ($mil) $6

Fund Codes

FundServ Code Load Code Sales Status
BMO70264

Investment Objectives

This fund’s objective is to provide long-term capital growth by investing primarily in equity securities of companies involved in disruptive genomic innovation from around the world.

Investment Strategy

These are the strategies the portfolio manager uses to try to achieve the fund’s objectives: invests primarily in global equity securities of companies across various sectors that are focused on and are expected to substantially benefit from extending and enhancing the quality of human and other life by incorporating technological and scientific developments and advancements in genomics into their business.

Portfolio Manager(s)

Name Start Date
Catherine D. Wood 05-24-2024
Dan White 05-24-2024
Nicholas Grous 05-24-2024

Management and Organization

Fund Manager BMO Investments Inc.
Advisor Ark Investment Management LLC
Custodian -
Registrar -
Distributor -
Auditor -

Investment Minimums

RSP Eligible Yes
PAC Allowed No
PAC Initial Investment -
PAC Subsequent -
SWP Allowed No
SWP Min Balance -
SWP Min Withdrawal -

Fees

MER 1.98%
Management Fee 1.75%
Load No Load
FE Max -
DSC Max -
Trailer Fee Max (FE) -
Trailer Fee Max (DSC) -
Trailer Fee Max (NL) 1.00%
Trailer Fee Max (LL) -

Join Fund Library now and get free access to personalized features to help you manage your investments.